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doi:10.1016/j.jtcvs.2006.09.023bjective: The study objective was to develop a treatment algorithm for cT2N0M0
sophageal cancer by determining (1) errors in clinical staging and (2) consequences of
vertreatment and undertreatment of incorrectly clinically staged patients.
ethods: Of 742 clinically staged patients, 61 (8.2%) had cT2N0M0 cancer; 45
nderwent surgery alone; 8 underwent surgery and postoperative adjuvant therapy;
nd 8 underwent induction therapy, then surgery. As reference, 31 of 666 patients
4.7%) who underwent surgery first had pT2N0M0 cancer and a 5-year survival of
1%  9.3%. Referent values were calculated from 445 clinically staged patients
ho underwent surgery first. Unmatched and matched survival comparisons were
ade using the log-rank test.
esults: Only 7 of 53 cT2N0M0 cancers treated with surgery first were pT2N0M0
13% positive predictive value). Of incorrectly staged cT2N0M0 cancers (46/53), 29
63%) were overstaged and 17 (37%) were understaged. Most overstaged cancers
ere pT1 (11 [38%] T1a and 15 [52%] T1b), and most understaged cancers were
N1 (13 [76%]). Matched overstaged patients treated by surgery alone (25/28) had
5-year survival similar to that of patients with pTNM (69%  9.8% vs 63% 
3%, P .8). Understaged patients did better at 5 years than patients with pTNM if
hey had postoperative adjuvant therapy, not surgery alone (43%  22% vs 10% 
.5%, P .17). Induction therapy decreased 5-year survival compared with all other
reatment strategies (13%  12% vs 52%  7.4%, P .05).
onclusions: Patients with cT2N0M0 cancers should undergo surgery first with lymph-
denectomy. Clinically understaged patients should receive postoperative adjuvant
herapy. In the unlikely event that patients with cT2N0M0 cancers are found to have an
ncommon pT2N0M0 cancer, they will have acceptable survival with surgery alone.
ecision making in stage-directed therapy of esophageal cancer is easy at the
extremes of stage grouping: surgery alone for early-stage cancers and
multimodality therapy for advanced-stage cancers. Patients with pT2N0M0
sophageal cancer have intermediate survival with surgery alone (Figure 1). If
ecisions could be made on the basis of pathologic stage, surgery alone would be a
ogical choice for this cancer because adjuvant therapy is toxic and unlikely to
easurably improve these patients’ survival. However, decisions must be made on
he clinical stage, and currently, this is guesswork for cT2N0M0 patients. The
urpose of this study was to develop a logical algorithm for treating this cancer by
etermining (1) errors in its clinical staging and (2) consequences of overtreatment
nd undertreatment of incorrectly clinically staged patients.
atients and Methods
atients
total of 742 patients with esophageal cancer who had clinical staging and esophagectomy
rom February 1987 through May 2005 were identified from the Cleveland Clinic Thoracic
urgery Database, which has been approved for use in research by the institutional review
oard. Three hundred forty patients underwent surgery alone, 105 patients underwent surgery
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G
TSnd postoperative adjuvant therapy, 121 patients underwent induc-
ion therapy and surgery, and 176 patients underwent induction
herapy, surgery, and postoperative adjuvant therapy.
linical Staging
linical staging of T and N classifications was obtained by esoph-
geal endoscopic ultrasound (EUS) performed under local sedation
fter flexible esophagoscopy. The currently available Olympus
choendoscope (Olympus Optical Co Ltd, Tokyo, Japan) (primar-
ly EU-M2, EU-M3, and EU-M20) was used. Clinical classifica-
ion of cT2 was invasion limited to the fourth ultrasound layer.1,2
linical classification of cN0 was no evidence of regional lymph
ode metastases. Classification was accomplished using estab-
ished criteria for size, shape, border, and ultrasound “texture,” and
as routinely assessed using the 7.5-MHz setting.2-4 Fifty-eight
atients had EUS fine-needle aspiration of regional and nonre-
ional lymph nodes. Clinical classification of cM0 was no evi-
ence of distant metastases; all patients underwent computed to-
ography, and 273 patients underwent fluorodeoxyglucose
ositron emission tomography.
rrors in Clinical Staging
eferent values for EUS clinical classification of cT, cN, and
TNM were calculated from 445 clinically staged patients who
nderwent surgery first. The results are presented as sensitivity,
pecificity, positive and negative predictive values, and accuracy
f EUS to identify T2, N0, and T2N0M0 cancers.5
onsequences of Treating Incorrectly Staged Patients
Overstaged patients. A total of 177 patients treated with sur-
ery alone hadpT2N0M0 cancer. Among these, 28 patients were
verstaged as cT2N0M0 and the remaining 149 patients were not.
or fair survival comparisons, differences between these 2 groups
f patients were accounted for with propensity methods.6,7 The
robability of being a patient with overstaged cT2N0M0 cancer
propensity score) was estimated from a logistic regression model
ontaining 5 variables: age, pT, histology, differentiation, and
urgical approach. Patients were then matched using the propensity
core. Twenty-five matched pairs were obtained.
Patient and tumor characteristics were compared between un-
atched and matched groups using the t test or chi-square test.
urvival after esophagectomy was estimated nonparametrically by
he Kaplan–Meier method8 and compared between unmatched and
atched groups using the log–rank test. Analyses were performed
sing SAS software (version 8, SAS Institute, Inc, Cary, NC).
Understaged patients. A total of 114 patients treated with
urgery alone had pT2N0M0 cancer; 10 patients were under-
taged as cT2N0M0, and 104 patients were not. One hundred
atients treated with surgery followed by adjuvant therapy had
pT2N0M0 cancer; 7 patients were understaged as cT2N0M0,
nd 93 patients were not. Propensity models were developed
Abbreviations and Acronyms
EUS endoscopic ultrasoundeparately for patients treated with surgery alone and patients *
18 The Journal of Thoracic and Cardiovascular Surgery ● Febrreated with surgery followed by adjuvant therapy. In each analy-
is, the probability of being an understaged cT2N0M0 patient was
stimated from a logistic regression model containing 3 variables:
T, pN, and pM. Patients were then matched using the propensity
core. Nine matched pairs were obtained for those treated with
urgery alone, and 7 matched pairs were obtained for those treated
ith surgery followed by adjuvant therapy. Comparisons were
ade as previously described.
resentation
ata are presented as frequencies and percentages or as means and
tandard deviations. Survival estimates are provided at selected
ime points, along with the standard error and number at risk.
igure 1. Survival after surgery alone for esophageal cancer
ccording to pTNM. Each step represents a death, and vertical
icks represent a censored patient.
ABLE 1. Referent values for clinical staging*
athologic finding
EUS determination Referent values (%)
cT2 Not cT2 Acc Sens Spec PV PV
T2 18 19 78 49 81 19 95
ot pT2 78 330
cN0 Not cN0
N0 185 89 71 68 78 83 60
N1 38 133
cT2N0M0 Not cT2N0M0
T2N0M0 7 17 86 29 89 13 96
ot pT2N0M0 46 375
US, Endoscopic ultrasound; Acc, accuracy, Sens, sensitivity; Spec, spec-
ficity, PV, positive predictive value; PV, negative predictive value.
Among 445 patients with surgery first who had esophageal EUS staging.
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TSesults
rrors in Clinical Staging
f 742 clinically staged patients, 61 (8.2%) had cT2N0M0
ancer and 53 (7.1%) had surgery as first therapy. Of the 445
linically staged patients who underwent surgery first, 24
ABLE 2. Pathologic stage groupings for 53 cT2N0M0 pa-
ients treated by surgery first
nterpretation and pathologic stage groupings No.
verstaged
0
pTisN0M0 3
I
pT1aN0M0* 11
pT1bN0M0† 15
orrectly staged
IIA
pT2N0M0 7
nderstaged
IIA
pT3N0M0 4
IIB
pT1bN1M0 4
pT2N1M0 1
III
pT3N1M0 7
IVB
pT2N1M1b 1
pT1a, intramucosal cancer. †pT1b, submucosal cancer.
ABLE 3. Comparison of unmatched and matched overstag
ariable
Unm
Overstaged
(n  28)
<
No. % N
ge (y)* 64  10.7
T
pT1 3 11
PT1a–lp 2 7.1
pT1a–mm 8 29
pT1b–inner 7 25
pT1b–outer 8 29
istology
Adenocarcinoma 23 82 1
Squamous cell 5 18
ifferentiation
Undifferentiated/poor/moderately poor 13 46
Moderate 8 29
Moderately well/well 7 25
urgical approach
Thoracotomy 19 70
Transhiatal/laparotomy 9 32 1p, Lamina propria; mm, muscularis mucosa; inner, inner half of submucosa; ou
The Journal of Thoracic5.4%) had pT2N0M0 cancer. Scoring matrices and referent
alues for T2, N0, and T2N0M0 are listed in Table 1.
Of the 53 cT2N0M0 patients treated with surgery first, 7
13%) were correctly staged, 29 (55%) were overstaged,
nd 17 (32%) were understaged (Table 2). Twenty-six over-
taged patients (90%) had pT1N0M0: 11 (38%) T1a (in-
ramucosal) and 15 (52%) T1b (submucosal). Thirteen
76%) understaged patients had pN1.
onsequences of Treating Incorrectly Staged Patients
Treatment of overstaged patients. Although survival af-
er surgery alone of 28 overstaged patients seemed to be
orse than that of 149 patients with pT2N0M0 cancer
reated by surgery alone (P .07, Figure E1), this was
ecause tumor characteristics and treatment of the groups
iffered. Overstaged patients had more cancers with high
T, squamous histology, and poor differentiation than the
omparison group, and were more likely to have a thora-
otomy (Table 3). When patients were matched, survival
as similar (P .8, Figure 2).
Treatment of understaged patients. Treating under-
taged cT2N0M0 patients by surgery alone (n  10) re-
ulted in poor survival, similar to that for 104 patients with
pT2N0M0 cancer (P .4; Figure E2, Table 4), and this
as also true of matched patients (P  .4; Figure 3, Table
). Treating understaged patients by surgery first followed
y adjuvant therapy (n  7) resulted in similar intermediate
urvival as for 93 such patients with pT2N0M0 cancer (P
.5; Figure E3, Table 5), and this was also true of matched
T2N0M0 patients
ed Matched
0M0 (n
149)
P
Overstaged
(n  25)
<pT2N0M0
(n25)
P% No. % No. %
9.9 .4 63  10.8 65  8.5 .6
.007 .9
24 3 12 4 16
27 2 8.0 2 8.0
26 7 28 8 32
12 6 24 5 20
11 7 28 6 24
.001 .6
99 23 92 24 96
1.3 2 8.0 1 4.0
.0001 .9
13 11 44 10 40
23 7 28 8 32
63 7 28 7 28
.001 1.0
27 16 64 16 64
73 9 36 9 36ed c
atch
pT2N

o.
62 
36
40
39
18
16
47
2
20
35
94
40
09ter, outer half of submucosa. *Mean  standard deviation.
and Cardiovascular Surgery ● Volume 133, Number 2 319
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G
TSatients (P .8; Figure 4, Table 5). In understaged patients,
urvival after surgery and postoperative adjuvant therapy
as better than after surgery alone (P .17, Figure 5).
mpact of Induction Therapy
mpirical treatment of 8 cT2N0M0 patients who had induc-
ion therapy before surgery resulted in poorer survival than
n those undergoing surgery first (P .05, Figure 6).
iscussion
rrors in Clinical Staging
urvival of patients with cT2N0M0 and pT2N0M0 cancers
s similar (Figure E4), from which one might infer that
linical staging accurately reflects pathologic staging. This
s not the case; on close examination, clinical staging seems
igure 2. Comparison of survival after surgery alone in over-
taged cT2N0M0 patients versus non-cT2N0M0 patients with
pT2N0M0 cancers (propensity-matched surgery-alone patients).
ormat is as in Figure 1.
ABLE 4. Comparison of unmatched and matched understa
athologic classification
Unmatched
Understaged
(n  10)
>pT2N0M0
(n  104)
No. % No. %
T
pT1b 1 10 4 3
pT2 2 20 7 6
pT3-4 7 70 93 89
N
pN0 3 30 25 24
pN1 7 70 79 76
M
pM0 9 90 93 90
pM1 1 10 11 11
20 The Journal of Thoracic and Cardiovascular Surgery ● Febro be nearly useless. The good survival of the majority of
atients who were overstaged balances the poor survival of
he minority of patients who were understaged, leading to
n intermediate pT2N0M0-like survival for the group.
However, overstaged patients were an atypical group,
omposed not of a balance of patients with superficial
ancer with either high-grade dysplasia or variably invasive
1 cancers,9 but of a majority with deeply invasive submu-
osal T1b cancers. We previously showed that survival is
imilar for such patients and those with pT2N0M0 tumors;
t is worse, however, for both these groups of patients than
or those with more superficial tumors.10 Thus, overstaging
rrors of ultrasound classification predominately occurred
bout the interface of the third (submucosa) and fourth
muscularis propria) ultrasound layers. Ultrasound layers
cT2N0M0 patients treated by surgery alone
Matched
P
Understaged
(n  9)
>pT2N0M0
(n  9)
PNo. % No. %
.2 1.0
1 11 1 11
1 11 1 11
7 78 7 78
.7 1.0
3 33 3 33
6 67 6 67
.9 —
9 100 9 100
igure 3. Comparison of survival after surgery alone in under-
taged cT2N0M0 patients versus non-cT2N0M0 patients with
pT2N0M0 cancers (propensity-matched surgery-alone patients).
ormat is as in Figure 1.ged
.8
.70 0 0 0
uary 2007
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G
TSre only an approximate reflection of this anatomic bound-
ry: The third ultrasound layer is composed of the submu-
osa and acoustic interface between the submucosa and
uscularis propria.11,12 Therefore, the anatomic informa-
ion necessary to differentiate deep T1b submucosal cancers
rom more superficial T2 cancers may not be available to
he ultrasonographer.
Classification errors in understaged patients were differ-
nt. Approximately one quarter of errors were in T, one
hird were in N, and the remaining were in both T and N.
pproximately 50% of patients with pT2 cancer have N1
egional nodal metastases.13 This underscores the need for
mproved technology to facilitate EUS fine-needle aspira-
ion of regional lymph nodes without false-positive cytol-
ABLE 5. Comparison of unmatched and matched understa
herapy
athologic classification
Unmatched
Understaged
(n  7)
>pT2N0M0
(n  93)
No. % No. %
T
pT1a 0 0 2 2
pT1b 3 43 6 6
pT2 0 0 4 4
pT3-4 4 57 81 87
N
pN0 1 14 15 16
pN1 6 86 78 84
M
pM0 7 100 76 82
pM1 0 0 17 18
igure 4. Comparison of survival after surgery followed by adjuvant
herapy in understaged cT2N0M0 patients versus non-cT2N0M0 pa-
ients with >pT2N0M0 cancers (propensity-matched similarly
reated patients). Format is as in Figure 1. r
The Journal of Thoracicgy resulting from the sampling needle passing through the
rimary cancer.
These overstaging and understaging errors in classifying
T2N0M0 reflect 3 sources: 2 anatomic boundaries and
egional lymph nodes. Although these errors lead to poor
etermination of T2N0M0 tumors, understanding their na-
ure actually allows this inaccurate EUS information to be
sefully interpreted for optimal treatment decision making.
cT2N0M0 patients treated by surgery followed by adjuvant
Matched
P
Understaged
(n  7)
>pT2N0M0
(n  7)
PNo. % No. %
.01 1.0
0 0 0 0
3 43 3 43
0 0 0 0
4 57 4 57
.9 1.0
1 14 1 14
6 86 6 86
.2 —
7 100 7 100
0 0 0 0
igure 5. Comparison of survival after surgery alone versus sur-
ery followed by adjuvant therapy in understaged cT2N0M0 pa-
ients. At 1 and 3 years, 4 and 2 patients remained at risk in the
ostoperative adjuvant therapy group, with 68% confidence limits
f 72% to 99% and 20% to 65% at these intervals, respectively.
fter surgery alone, 5 and 3 patients remained at risk, with
onfidence limits of 34% to 66% and 16% to 44% at 1 and 3 years,ged
.2
.4
.3espectively. Format is as in Figure 1.
and Cardiovascular Surgery ● Volume 133, Number 2 321
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TSonsequences of Treating Incorrectly Staged Patients
s well as being more deeply invasive, cancers of over-
taged patients were more likely to be poorly differentiated
nd of squamous histology. This accounts in part for the
urvival difference seen in overstaged versus other patients
ith pT2N0M0 cancer. In addition, esophagectomy by
horacotomy, a predictor of worse survival in patients with
uperficial cancers than transhiatal resection,14 reflects our
ractice of performing a 2-field lymphadenectomy in pa-
ients with a high probability of regional lymph node me-
astases. This information is crucial for prognostication and
ostoperative treatment decision making and seems to be
ppropriate for cT2N0M0 tumors. Further, there seems to
e no adverse consequences of treating overstaged
T2N0M0 patients by esophagectomy first.
Understaged patients did as poorly as other patients with
pT2N0M0 cancer, a reflection of the impact of pT3 and
N1 classification on survival. However, as previously
hown in matched patients, postoperative adjuvant therapy
mproves survival.14 Thus, consequences of understaging
T2N0M0 patients can be mitigated by accurate pathologic
taging and use of adjuvant therapy after esophagectomy.
mpact of Induction Therapy
espite the small number of patients, the association of
nduction therapy with the poor survival of cT2N0M0 pa-
ients is striking. This is due not only to treatment toxicity
igure 6. Comparison of survival after induction therapy followed
y surgery versus surgery first in cT2N0M0 patients. At 1 and 3
ears, 37 and 24 patients remained at risk in the surgery-first
roup, with 68% confidence limits of 84% to 73% and 47% to 61%
t these intervals, respectively. After induction therapy, 4 patients
nd 1 patient remained at risk, with confidence limits of 32% to
8% and 1% to 24% at 1 and 3 years, respectively. Format is as in
igure 1.ut also to cancer deaths, because 5 of 7 deaths occurred in
22 The Journal of Thoracic and Cardiovascular Surgery ● Febratients with early cancer recurrence. We know of no trial
f induction therapy that includes cT2N0M0 patients, nor is
uch a trial likely to be conducted given the present knowl-
dge; thus, these results should not be ignored, but they
hould be considered cautiously. However, even if results
ere at the upper confidence limits of our experience rather
han the mean, there would be no survival advantage of
nduction therapy.
trengths and Weaknesses
his is a single-institution study of an uncommon cancer for
hich treatment was nonrandomized and heterogeneous
ver an 18-year period. Propensity analysis was used to
inimize bias.
Because the tumor is uncommon, its treatment has not
een subjected, to our knowledge, to rigorous study. Until it
as, we have exploited heterogeneity in treatment selection
o derive a clinically logical strategy, supported by these
onrandomized data, that should minimize harm to over-
taged patients while providing an effective alternative for
nderstaged patients. Nevertheless, our protocols for man-
ging esophageal cancer do not permit us to examine the
arge variety of other treatments. Some survival differences
n our own treatment strategies could have been due to
hance or may be real, but small sample sizes precluded all
ut rather large differences from being detected as distinc-
ive. Despite practicing utmost care, clinical staging was
ncorrect in the majority of cT2N0M0 patients, a reflection
f current technology. It is possible, but not yet demon-
trated, that new generations of echoendoscopes may im-
rove the clinical staging of patients with T2N0M0 cancers.
reatment Algorithm
atients with cT2N0M0 cancers should undergo surgery
rst, with lymphadenectomy. Clinically understaged pa-
ients should receive postoperative adjuvant therapy. In the
nlikely event that any cT2N0M0 patients are found to have
T2N0M0 cancer, they will have acceptable survival with
urgery alone; the role of postoperative adjuvant therapy is
et to be defined.
The authors thank Tess Parry for editorial assistance and Ann
amber for data entry.
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iscussion
r Steven G. Swisher (Houston, Tex). This study reviews the
utcome of an uncommon subset of patients with esophageal
ancer: those patients with clinical T2N0 tumors as defined by
US. The authors make the observation that this group of patients
eem to be difficult to accurately stage by EUS, with only 7 of 53
atients (13%) actually having a pathologic T2N0 tumor. Some
5% of the EUS-staged patients were overstaged and 32% were
nderstaged, making proper treatment decisions difficult. The au-
hors then evaluate the outcome of these patients and suggest that
he optimal treatment for these patients is surgery first with post-
perative chemoradiation reserved for those patients who have
een understaged.
The article is to be commended for attempting to address an
ncommon group of patients for whom little data are available and
reatment decisions have not been defined. There are, however,
everal limitations to this study. It is retrospective and nonrandom-
zed, and because of this, it is subject to bias and selection. This
tudy was performed over a long period of time (20 years), with a
mall number of heterogeneous patients who were treated with
everal different treatment strategies. Because of these inherent
imitations, accurate treatment assessments and recommendations
re difficult to make even when performed with the aid of sophis-
icated statistical analyses.
I have several questions for the author. First, the accuracy of
US staging for T2 esophageal cancers is much lower than that
eported by recent groups who have used new EUS probes that
perate at a higher frequency (15-20 MHz), as opposed to the 7.5
Hz described here, in which the esophageal wall can be visual-
zed as a series of 7 or 9 layers. Would the use of these more
ccurate EUS miniprobes eliminate some of the staging inaccura-
ies reported in this study? e
The Journal of ThoracicDr Rice. No doubt the limitation of staging is ultrasound
echnology. As we look at the study period, we find that staging
ccuracy did not get any better over time, although we do use the
2-MHz probe to look within the wall and the 7.5-MHz probe to
ook distantly. The problem with adding more and more layers is
hat you have, of course, more and more interfaces to deal with.
o, although increasing technology may seem attractive, it could
dd more areas for error.
Dr Swisher. Second, I believe that you would agree it is
ifficult to come up with absolute conclusions about treatment
ecause this is a small, retrospective, nonrandomized study per-
ormed over a 20-year time period. How did the authors select the
patients treated with postoperative adjuvant treatment? Was the
ecision made because of age or performance status or because of
feeling by the surgeon that the tumor was at high risk for
ecurrence?
Dr Rice. There were 8 patients over approximately 18 years
ho received induction chemoradiation therapy, and, yes, they
robably were treated a little earlier in the series; now, we would
ever consider anyone with disease confined to the wall for induc-
ion therapy. Certainly in these 8 patients, there is a small amount
f induction toxicity and many tumor deaths, suggesting inaccu-
acy in staging. That is the best we could do. I agree it is a small
umber, but you must realize that it took us nearly 20 years to
ccumulate this experience; at our institution, where we perform
0 to 100 resections a year, that is only 2 patients per year.
Dr Swisher. Third, why do the authors think that their induc-
ion therapy experience was associated with such a poor outcome
n their study? At MD Anderson we reviewed 21 patients who
ere treated with preoperative chemoradiation and had EUS-
efined T2N0 tumors. They were treated with induction chemora-
iation since 1997, and their overall survival is 67% at 3 years
ather than the 13% 3-year survival reported by this study. Was the
ncreased toxicity reported by your group caused by the hyperfrac-
ionated radiation therapy and paclitaxel that were used?
Dr Rice. Only 1 of 7 deaths was due to toxicity; 6 were due to
ecurrent cancer.
Dr Mark J. Krasna (Baltimore, Md). Tom, as always, I
ompliment you and your group for helping to elucidate all of the
ne intricacies in the management of esophageal cancer, the stage-
pecific approach.
I will just reiterate what we just heard from Dr Swisher, that to
ake any kind of conclusion based on 7 of 53 patients would be
nappropriate when we walk out of this room, but we appreciate
he chance to discuss it. I do advise more than anything to caution
gainst what I now have heard several times as a tendency among
horacic surgeons to adopt a postoperative adjuvant therapy ap-
roach in dealing with patients with any stage of esophageal
ancer. To my knowledge, there are only 2 positive trials that
ould support that approach. One is a Chinese trial of adjuvant
adiation therapy alone for patients with esophageal cancer. The
nly other data that are available that are either prospective or
andomized are the results of the Gastric Cancer Study, which
ncluded patients who had total gastrectomies with D1, D2 resec-
ions, radical lymphadenectomies, and most of them splenecto-
ies. So, again, I would just caution, although I know yourxperience is excellent, to generalize this, that people not walk out
and Cardiovascular Surgery ● Volume 133, Number 2 323
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G
TSf the room thinking that there is a proven role for adjuvant
adiation or chemoradiation for esophageal cancer.
Dr Rice. Can I turn that back to you? Where is the evidence for
he benefit of induction therapy? As surgeons, I would plead with
ou to do the operation first whenever possible. Then at least you
now the pathologic stage and can decide how to treat your patient.
f you are using induction chemoradiation therapy, two thirds of
our patients will not respond. That is as bad as giving them
ostoperative adjuvant therapy based on matched data or some
uestionable phase III data. But I stand, as you stand, with no
hase III study to help us. So, as a surgeon, take the cancer out
rst. You’ll be happy. At least you will know the pathologic stage.
Dr Krasna. Just to clarify, I do think that there are 3 phase III
rials out there, including the first one that was presented from the
roup in Michigan, as well as the Walsh study and recently the
ntergroup trial (CALGB 9781). Although all were small and some
ere questionable in terms of the long-term 5-year survival, espe-
ially for the Michigan trial, 2 of those 4 clearly showed a
ignificant advantage in 5-year survival, not just 1-, 2-, and 3-year
urvivals, with trimodality therapy over surgery alone.
Dr Rice. But two thirds of your patients are getting therapy
hey will not benefit from: toxic high-dose therapy.
Dr Krasna. In 2 of those trials, that’s correct. One of the trials
as a stage-specific approach.
Dr Steven DeMeester (Los Angeles, Calif). I’m glad to see that
our study is echoing some of the data we have presented as well,
hat patients, regardless of the size of the tumor (even in our
xperience, T3 tumors that are N0), have an excellent survival. I
hink that’s an important message, that the lymph node status is
uch more important than the size of the tumor.
I am a bit surprised how 10% of patients could be overstaged
hen they had only high-grade dysplasia. Did those patients have
biopsy that showed cancer, leading to the EUS that gave you the
isreading, or did they never have a biopsy of cancer? The
uestion is, how did that happen?
Dr Rice. That is only 3 patients.
Dr DeMeester. That’s 10% though.
Dr Rice. It’s 10%, and they did have a mass in a segment ofigh-grade dysplasia, but the biopsy was read as invasive cancer. g
24 The Journal of Thoracic and Cardiovascular Surgery ● FebrDr Antoon Lerut (Leuven, Belgium). You didn’t say anything
bout the lymph node ratio. How many lymph nodes were in-
olved and what was the ratio? Is the burden of lymph node
nvolvement comparable to what you find in the patients with T3?
ould the lymph node ratio be helpful in discriminating whether
ou would see that as an indication for adjuvant chemo/chemora-
iotherapy?
Dr Rice. Once we find N1 disease postoperatively, we try to
dminister postoperative adjuvant therapy. There is no doubt that
n our experience if a patient has 1 or 2 positive nodes, he or she
oes better than if 3 or more positive nodes are present, but that
urvival advantage is 10% versus 24% at 5 years. Still, if you want
o leave those patients with low lymph node burden unprotected,
hen that would be a way to direct your postoperative adjuvant
herapy.
Dr Joe B. Putnam Jr (Nashville, Tenn). I have no conflicts.
Tom, I appreciated the information that you presented here
oday and the lively discussion that has ensued.
As noted by the discussants, there are significant differences in
urvival that have been noted between single institutions. On the
asis of multiple single-institution studies, we have created para-
igms of cancer treatment, and there is a significant lack of
ulti-institutional trials in the prospective fashions. We have been
uccessful in some phase II studies, and phase III studies have not
een adequately subscribed to by our surgeons, medical oncolo-
ists, and radiation oncologists in a way that would allow rapid
ccrual, completion, and timely publication of the results. I would
ike your opinion as to the strategies that we can use to develop
hese multi-institutional trials to answer these significant problems,
hese significant questions that we have as surgeons and members
f multidisciplinary teams in the treatment of our patients with
sophageal cancer.
Dr Rice. For a phase III multi-institutional study, you obvi-
usly have to use high-volume centers. So, the first step is to get
hese centers to agree to participate. I believe that including low-
olume centers will eliminate any survival advantage through
ncreased operative or treatment mortality. The big boys have to
et together.
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G
TSigure E1. Comparison of survival after surgery alone in over-
taged cT2N0M0 patients versus non-cT2N0M0 patients with
pT2N0M0 cancers (unmatched patients treated with surgery
lone). Format is as in Figure 1.F
t
The Journal of Thoracic aigure E2. Comparison of survival after surgery alone in under-
taged cT2N0M0 patients versus non-cT2N0M0 patients with
pT2N0M0 cancers (unmatched patients treated with surgery
lone). Format is as in Figure 1.igure E3. Comparison of survival after surgery followed by ad-
uvant therapy in understaged cT2N0M0 patients versus non-
T2N0M0 patients with >pT2N0M0 cancers (unmatched patients
reated similarly). Format is as in Figure 1.igure E4. Survival in surgery-first cT2N0M0 patients versus pa-
ients with pT2N0M0 tumors. Format is as in Figure 1.nd Cardiovascular Surgery ● Volume 133, Number 2 324.e1
